Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
Britain Courts Anthropic Amid US Defense Department Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CARLSBAD, Calif., July 20, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release second quarter 2017 financial results after the close of trading on Thursday, August 3, 2017. The Company’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 49156714. The webcast will also be available on the SeaSpine website following the completion of the call. To listen to the webcast, please visit the investor relations section of the SeaSpine website at www.seaspine.com.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal instrumentation solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal instrumentation portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal instrumentation product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact Lynn Pieper (415) 937-5402 [email protected]
